Privately-held German drugmaker Boehringer Ingelheim reported a rise of 17% in its net sales for 2022 compared to the prior year.
Boehringer's net sales figure for the year stood at 24.15 billion euros ($26.2 billion) representing a healthy increase on 2021’s 20.62 billion euros.
The likely candidates of Jardiance (empagliflozin), a drug that treats type 2 diabetes and chronic heart failure, and the idiopathic pulmonary fibrosis product Ofev (nintedanib), proved key to the sales growth.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze